This inventor holds 1 USPTO granted patent. Top assignee: The University of British Columbia. Active years: 2001.
Company Filing History:
Years Active: 2001
Title: Michael Kalchman: Innovator in Huntington's Disease Research
Introduction
Michael Kalchman is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of medical research, particularly in understanding Huntington's disease. His innovative work has led to the development of a patent that explores the interaction between specific proteins and the Huntington's disease gene.
Latest Patents
Kalchman's most recent patent focuses on apoptosis modulators that interact with the Huntington's disease gene. This patent describes a family of proteins, including a specific human protein designated as HIP1, which interacts differently with the gene product of a normal (16 CAG repeat) and an expanded (>44 CAG repeat) HD gene. The expression of the HIP1 protein is enriched in the brain, and its sequence analysis indicates the presence of a death effector domain (DED), suggesting an apoptotic function. This research provides insights into the role of huntingtin and HIP1 in the pathology of Huntington's disease, offering potential therapeutic avenues.
Career Highlights
Michael Kalchman is affiliated with the University of British Columbia, where he conducts his research. His work has been instrumental in advancing the understanding of Huntington's disease and its underlying mechanisms. He has been recognized for his innovative approach to addressing complex medical challenges.
Collaborations
Kalchman has collaborated with esteemed colleagues, including Michael R. Hayden and Abigail Hackam. These partnerships have enriched his research and contributed to the advancement of knowledge in the field of neurodegenerative diseases.
Conclusion
Michael Kalchman's contributions to the understanding of Huntington's disease through his innovative research and patent on apoptosis modulators highlight his role as a leading inventor in the medical field. His work continues to pave the way for potential therapies that could benefit individuals affected by this challenging condition.